Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapies for triple negative breast cancer.
Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Andreopoulou E, et al. Expert Opin Pharmacother. 2015 May;16(7):983-98. doi: 10.1517/14656566.2015.1032246. Expert Opin Pharmacother. 2015. PMID: 25881743 Free PMC article. Review.
PARP Inhibitors in Breast Cancer: Why, How, and When?
Paradiso A, Andreopoulou E, Conte P, Eniu A, Saghatchian M. Paradiso A, et al. Among authors: andreopoulou e. Breast Care (Basel). 2018 Jul;13(3):216-219. doi: 10.1159/000490746. Epub 2018 Jun 20. Breast Care (Basel). 2018. PMID: 30069183 Free PMC article. No abstract available.
Expert Discussion: HER2-Positive Breast Cancer.
Foukakis T, Matikas A, Oikonomidou O, Andreopoulou E, Mavroudis D. Foukakis T, et al. Among authors: andreopoulou e. Breast Care (Basel). 2021 Aug;16(4):422-428. doi: 10.1159/000516965. Epub 2021 Jun 17. Breast Care (Basel). 2021. PMID: 34602950 Free PMC article. No abstract available.
Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.
Fasano GA, Bayard S, Chen Y, Varella L, Cigler T, Bensenhaver J, Simmons R, Swistel A, Marti J, Moore A, Andreopoulou E, Ng J, Brandmaier A, Formenti S, Ali H, Davis M, Newman L. Fasano GA, et al. Among authors: andreopoulou e. Breast Cancer Res Treat. 2022 Feb;192(1):163-173. doi: 10.1007/s10549-021-06481-4. Epub 2022 Jan 13. Breast Cancer Res Treat. 2022. PMID: 35022867
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.
Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Adelson K, et al. Among authors: andreopoulou e. NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016. NPJ Breast Cancer. 2016. PMID: 28721390 Free PMC article.
Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.
Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, Cerchietti L, Vahdat L, Brown KA, Andreopoulou E, Elemento O, Chang J, Inghirami G, Gao D, Ryu S, Mittal V. Yomtoubian S, et al. Among authors: andreopoulou e. Cell Rep. 2020 Jan 21;30(3):755-770.e6. doi: 10.1016/j.celrep.2019.12.056. Cell Rep. 2020. PMID: 31968251 Free article.
70 results